阿里拉姆制药 ALNY 深 沪
交易中 05-11 10:33:38 美东时间
293.80
-0.700
-0.24%
华盛通- 最 高306.03
- 今 开294.26
- 成交量 100.02万股
- 最 低 292.32
- 昨 收 294.50
- 总市值 3554.98万
- 52周最高 495.55
- 市盈率 静 --
- 换手率 826.60%
- 52周最低 284.19
- 委 比 98.10%
- 总股本 0.00亿
- 历史最高 495.55
- 量 比 8.05
- 振 幅 4.66%
- 历史最低 1.10
- 每 手 1
- 风险率 66.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For April 30, 2026
Companies Reporting Before The Bell • Sonic Automotive (NYSE:SAH) is projected ...
04-30 19:11
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.
03-11 02:49
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $1.13 billion in milestone payments.
03-06 02:35
Alnylam Canada ULC Wins CDA Reimbursement Recommendation For AMVUTTRA In ATTR Cardiomyopathy
Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025,
03-02 21:14
Alnylam Pharmaceuticals Q4 Earnings Assessment
Alnylam Pharmaceuticals (NASDAQ:ALNY) released its Q4 earnings on Thursday, Feb...
02-12 21:08
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale
Alnylam outlines its 2030 strategy, targeting TTR leadership, pipeline expansion, and strong revenue growth backed by rising product sales.
01-13 02:33
Alnylam Pharma To Invest $250M To Advance siRNA Enzymatic-Ligation Manufacturing Facility
New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipelineFDA has accepted Alnylam's enzymatic ligation manufacturing platform into its
2025-12-17 21:03
Health Canada Approves Alnylam's AMVUTTRA For ATTR Cardiomyopathy
Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-type or
2025-12-16 21:11
Is Alnylam Entering A Corrective Phase After A Strong Run?
A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.
2025-12-16 20:04
